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Objective. To investigate the expression and tis-
sue distribution of Th9-related cytokines in patients
with psoriatic arthritis (PsA).
Methods. Quantitative gene expression analysis
of Th1, Th17, and Th9 cytokines was performed in
intestinal biopsy samples obtained from patients with
PsA, HLA2B272positive patients with ankylosing
spondylitis (AS), patients with Crohn’s disease (CD),
and healthy controls. Expression and tissue distribu-
tion of interleukin-23 (IL-23), IL-17, IL-22, IL-9, and
IL-9 receptor (IL-9R) were evaluated by immunohisto-
chemistry and confocal microscopy. Flow cytometry was
used to study the frequency of Th9 cells among periph-
eral blood, lamina propria, and synovial fluid mononu-
clear cells. The functional relevance of IL-9R
expression on epithelial cells was assessed in functional
in vitro studies. Th9 cells in synovial tissue from
patients with PsA were also studied.
Results. Subclinical gut inflammation in PsA
patients was characterized by a clear Th17 and Th22,
but not Th1, polarized immune response. Unlike AS
and CD, a strong and significant up-regulation of IL-9
was observed in PsA gut, especially among infiltrating
mononuclear cells, high endothelial venules, and Pan-
eth cells. IL-92positive mononuclear cells were demon-
strated to be in large part Th9 cells. IL-9 overexpression
was accompanied by significant Paneth cell hyperplasia.
Paneth cells strongly overexpressed IL-9R, and stimula-
tion of epithelial cells, isolated from PsA patients, with
IL-9 resulted in overexpression of a-defensin 5 and
IL-23p19. Peripheral and synovial expansion of a4b71
Th9 cells was also observed in patients with PsA.
Increased expression of IL-9 and IL-9R was also found
in synovial tissue.
Conclusion. Strong IL-9/Th9 polarization seems
to be the predominant immunologic signature in
patients in PsA.
The relationship between inflammatory bowel
disease and psoriasis has been investigated in epidemio-
logic, genetic, and immunologic studies for many years,
and recently, the relative risk of incident Crohn’s dis-
ease (CD) and ulcerative colitis in patients with psoria-
sis and psoriatic arthritis (PsA) has been described (1).
However, to date the role of different Teff cell subsets
in PsA gut pathology has not been addressed. The path-
ogenesis of PsA seems to be multifactorial, and immu-
nologically driven by a mixed Th1 and interleukin-23
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(IL-23)/Th17 response (2–4). Recently IL-9, a member
of the IL-2 cytokine family that is secreted by naive
CD41 T cells in response to transforming growth factor
b (5), has been demonstrated to be involved in the path-
ogenesis of several autoimmune diseases, including
psoriasis (6–9). In the present study we aimed to char-
acterize the subclinical gut inflammation of PsA, to
investigate the expression and tissue distribution of IL-9/
Th9–related molecules, and to evaluate the effect of
tumor necrosis factor inhibitor (TNFi) and ustekinumab
therapy on circulating Th9 cells.
PATIENTS AND METHODS
Patients. Intestinal biopsy specimens were obtained
from 25 patients with PsA fulfilling the criteria of the Classifi-
cation of Psoriatic Arthritis Study Group (10) (11 with pre-
dominant axial involvement) and from 15 patients with HLA–
B27–positive ankylosing spondylitis (AS) fulfilling the New
York criteria (11), without gastrointestinal symptoms. Ten
patients with CD and 20 healthy controls who underwent ileo-
colonoscopy for routine clinical evaluation were also included
in the study. Synovial tissue samples were also obtained from
an additional 5 PsA patients with active disease at the time of
sample collection and from 5 patients with osteoarthritis (OA)
(12). Baseline characteristics of the patients and controls are
shown in Supplementary Table 1 (on the Arthritis & Rheuma-
tology web site at http://onlinelibrary.wiley.com/doi/10.1002/
art.39649/abstract). Disease activity in patients with PsA with
axial involvement and patients with AS was assessed with the
Bath Ankylosing Spondylitis Disease Activity Score (BAS-
DAI) (13); the 28-joint Disease Activity Score (DAS28) (14)
was used to evaluate disease activity in patients with PsA and
peripheral disease, and the Crohn’s Disease Activity Index
(CDAI) (15) was used to assess patients with CD. The severity
of psoriasis was evaluated by the Psoriasis Area and Severity
Index (PASI) (16). Collection of samples was approved by the
local ethics committee and the University of Palermo Institu-
tional Review Board, and informed consent was obtained from
all patients and controls.
Histomorphologic grading and immunohistochemis-
try analysis. Biopsy specimens were evaluated by 2 experi-
enced pathologists with expertise in inflammatory bowel
diseases (AR and AC) who were blinded with regard to clini-
cal data. Interrater agreement between the 2 pathologists, cal-
culated with Cohen’s kappa coefficient, was 0.85.
Gut specimens from patients with PsA and AS were
assessed histologically for the presence of inflammation and
classified according to the stage of histologic severity, as fol-
lows (17): stage 05normal histopathologic findings; stage
15 lymphoid hyperplasia with increased inflammatory cell
content in the lamina propria without evidence of cryptitis or
epithelial abnormalities; stage 25 diffuse increase of inflam-
matory cells in the lamina propria with crypt distortion, hyper-
plasia of crypt cell epithelium, infiltration of neutrophils, and
crypt abscesses; stage 35 ulcerations with or without epitheli-
oid granulomas. Lymphoid follicles were identified using CD3/
CD19/CD21 immunostaining.
The degree of inflammation was also evaluated in
synovial tissue obtained from 5 patients with PsA and, as con-
trols, from 5 patients with end-stage OA who were undergoing
knee joint replacement surgery. The grade of tissue inflamma-
tion was also assessed by evaluating the number of CD31,
CD191, and CD681 cells. Immunohistochemistry analysis
was performed as previously described (18); antibodies used
are listed in Supplementary Table 2 (http://onlinelibrary.wiley.
com/doi/10.1002/art.39649/abstract). The number of immuno-
reactive cells and lymphoid follicles was determined by counting
the reactive cells/lymphoid follicles seen on photomicrographs
obtained from 3 randomly and independently selected high-
power fields (hpf).
To specifically address the nature of IL-9–producing
cells, double staining for Th2 (IL-4/IL-9), Th17 (IL-9/IL-17),
and Paneth cells (IL-9/a-defensin 5) and triple staining for
Th9 cells (CD4/IL-9/PU.1) were performed on paraffin-
embedded synovial and ileal sections. Sections were treated
with fluorescein isothiocyanate–, rhodamine red–, or Cy5-
conjugated anti-mouse or anti-rabbit antibodies (Invitrogen)
plus RNase (200 ng/ml) and counterstained using TOTO-3
iodide (642/660; Invitrogen) or DAPI (Life Technologies).
Confocal microscopy was used to assess fluorescence staining.
RNA extraction and quantitative TaqMan real-time
reverse transcription–polymerase chain reaction (RT-PCR)
analysis of ileal biopsy specimens. Total RNA was extracted
using a Qiagen RNeasy Mini kit, with on-column DNase I
digestion. A total of 1 mg of RNA was reverse-transcribed to
complementary DNA using a ThermoScript First-Strand
cDNA Synthesis kit (Invitrogen). For quantitative TaqMan
real-time PCR, sets of primers and probes (Supplementary
Table 2, http://onlinelibrary.wiley.com/doi/10.1002/art.39649/
abstract) were obtained from Applied Biosystems. Samples
were run in triplicate using a Step-One Real-Time PCR system
(Applied Biosystems). Relative differences in gene expression
between controls and patients were determined using the DDCt
method as previously described (9). Final values were expressed
as fold induction compared to controls.
Peripheral blood mononuclear cell (PBMC) and
synovial fluid mononuclear cell (SFMC) isolation and flow
cytometry. PBMCs were obtained as previously described
(19) from 5 of the PsA patients in whom ileocolonoscopy was
also performed and from 9 additional PsA patients (before
and after TNFi treatment in 5 and before and after ustekinu-
mab treatment in 4), 10 AS patients, 10 CD patients, and 10
healthy controls. SFMCs were also obtained from 5 PsA
patients who underwent ileocolonoscopy and 5 OA patients.
Cell viability (assessed by trypan blue dye exclusion) was
always .95%. Four-color flow cytometric analysis was per-
formed using a FACSCalibur (BD Biosciences). At least 50,000
cells (events), gated on lymphocytes or monocyte/macrophage
regions, were acquired for each sample. Antibodies used are
listed in Supplementary Table 2 (http://onlinelibrary.wiley.com/
doi/10.1002/art.39649/abstract).
Cell cultures. Intestinal epithelial cells were isolated
from ileal samples from 5 PsA patients and 5 controls as previ-
ously described (20) and cultured in 24-well flat-bottomed
plates (Becton Dickinson Labware) at a density of 1 3 106
cells in 1 ml RPMI 1640 medium with 10% fetal calf serum,
2 mM L-glutamine, 20 nM HEPES, and 100 units/ml penicillin/
streptomycin with or without recombinant IL-9 (0.1 ng/ml or
10 ng/ml; R&D Systems). Cells were incubated at 378C in a
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humidified atmosphere containing 5% CO2 for 48 hours, and
levels of IL-17, IL-22, IL-23, retinoic acid receptor2related
orphan nuclear receptor, and STAT-3 were then determined
by RT-PCR.
Statistical analysis. The statistical significance of dif-
ferences between groups was calculated by Student’s t-test or
the nonparametric Mann-Whitney test. Paired samples were
analyzed by Wilcoxon’s signed rank test. P values less than
0.05 were considered significant.
RESULTS
Subclinical gut inflammation in PsA patients is
characterized by histologic inflammation and Paneth
cell hyperplasia. All of the patients with CD had active
disease (mean CDAI score 311 [range 2002 430]). The
endoscopic appearance of ileum seen on colonoscopy
demonstrated an absence of macroscopic alterations in
10 of the PsA patients and 8 of the AS patients. The
presence of mucosal erythema and erosions was
observed in the remaining PsA, AS, and CD patients.
Stage 02 1 lesions were observed in 6 PsA patients and
4 AS patients without macroscopic involvement (24%
and 26.7% of the PsA group and the AS group, respec-
tively), stage 2 lesions were observed in 12 PsA patients
(4 without macroscopic involvement) and 7 AS patients
(4 without macroscopic involvement) (48% and 46.7%
of the PsA and AS groups, respectively), and stage 3
lesions were observed in 7 PsA patients and 4 AS
patients (28% and 26.7%, respectively).
Similar to findings in AS, PsA patient ileum
exhibited an increased number of infiltrating inflamma-
tory CD31, CD191, and CD681 cells (Figures 1B, C,
and H2K and Supplementary Table 3, on the Arthritis
& Rheumatology web site at http://onlinelibrary.wiley.
com/doi/10.1002/art.39649/abstract), an increased num-
ber of lymphoid follicles (mean6SEM 2.56 0.9/hpf in
PsA patients compared to 1.46 0.6 in healthy controls;
P, 0.05) and significant Paneth cell hyperplasia (Fig-
ures 1D and G and Supplementary Table 3), which cor-
related with the grade of intestinal inflammation
(number of Paneth cells 66 0.72/hpf in histologic stage
3, 5.26 0.84 in stage 2, and 3.46 0.88 in stage 0 – 1).
Paneth cell hyperplasia was also accompanied by
increased expression of messenger RNA (mRNA) for
Paneth cell–derived antimicrobial peptides, such as a-
Figure 1. High levels of tissue inflammation and Paneth cell hyperplasia characterize subclinical gut inflammation in psoriatic arthritis (PsA).
A–D, Representative images of hematoxylin and eosin–stained ileal sections from patients with PsA. Arrowheads in D indicate Paneth cells. E
and F, Representative images of a-defensin 5 staining in samples from a healthy control (HC) (E) and a patient with PsA (F). G, Semiquantita-
tive evaluation of Paneth cells (per high-power field [hpf]) in patients with PsA, ankylosing spondylitis (AS), and Crohn’s disease (CD) and in
healthy controls. H–J, Inflammatory infiltrating cells and CD3-positive cells (H), CD19-positive cells (I), and CD68-positive cells (J) in PsA gut.
K, Semiquantitative evaluation of CD3-, CD19-, and CD68-positive cells (per hpf) in patients with PSA, AS, and CD and healthy controls. L
and M, Relative levels of mRNA for a-defensin 5 (L) and SOX9 (M), assessed by quantitative reverse transcription2polymerase chain reaction,
in ileal samples from PsA patients (n5 25) compared to healthy controls (n5 20). Values in G and K2M are the mean6 SEM. * 5 P , 0.05
versus controls. Original magnification 3 250 in A, E, F, and H2J. Color figure can be viewed in the online issue, which is available at http://
onlinelibrary.wiley.com/journal/doi/10.1002/art.39649/abstract.
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defensin 5, and of the transcription factor SOX9, which
is involved in Paneth cell differentiation (21) (Figures
1L and M). No differences in the degree of tissue
inflammation and/or number of infiltrating cells were
observed between patients who were taking nonsteroi-
dal antiinflammatory drugs (NSAIDs) and those who
were not (data not shown). Collectively, these data con-
firm that in patients with PsA, similar to patients with
AS, the ileum is characterized by subclinical histologic
inflammation.
Th1 and Th17 polarization in the gut of
patients with PsA. We next investigated the expression
of cytokines involved in the Th1 and IL-23/Th17 axis.
Unlike the findings in CD, and similar to those in AS,
Th1 cytokines were not significantly overexpressed in
PsA (Figures 2A–C). With regard to Th17 cells, a clear
overexpression of IL-17 and IL-22 mRNA (Figures 2D
and E) was demonstrated in PsA patients. Immunohis-
tochemistry results confirmed the RT-PCR data demon-
strating strong up-regulation of IL-17 (Figures 2F–H
and J) and IL-22 (Figures 2K2M and O and Supple-
mentary Table 3, on the Arthritis & Rheumatology web
site at http://onlinelibrary.wiley.com/doi/10.1002/art.39649/
abstract) in PsA patients, at levels similar to those
observed in patients with CD.
IL-9 overexpression and Th9 polarization in
the gut of patients with PsA. We next aimed to investi-
gate in more detail the dominant cytokine pathways
involved in subclinical gut inflammation in PsA. Based
on recent reports indicating a key role of IL-9 in the
pathogenesis of psoriasis (6,22), we studied the expres-
sion of IL-9 and Th9 in the gut of PsA patients. We first
assessed ileal biopsy specimens by RT-PCR for IL-9
and Th9-related transcription factor mRNA expression.
Levels of IL-9, PU.1, and interferon regulatory factor 4
mRNA were significantly up-regulated in the gut of PsA
patients, especially in those with stage 2–3 lesions, but
not in the gut of CD patients, AS patients, or controls
(Figures 3A–C). In order to confirm IL-9 mRNA
expression, paraffin sections of ileal specimens from
patients and controls were stained with anti–IL-9 anti-
body. IL-9 immunoreactivity was observed among infil-
trating mononuclear cells (Figures 3D–F), high
endothelial venules (Figure 3F), and epithelial cells
Figure 2. Th1 and Th17 cytokines in the gut of patients with PsA. A–E, Relative levels of mRNA for interferon-g (IFNg) (A), interleukin-12
(IL-12) (B), IL-6 (C), IL-22 (D), and IL-17 (E), assessed by quantitative reverse transcription2polymerase chain reaction, in ileal samples from
patients with PsA, AS, and CD and healthy controls. F2H, Representative photomicrographs showing IL-17 immunostaining in samples from a
patient with PsA (F), a patient with AS (G), and a healthy control (H). J, Semiquantitative evaluation of IL-172positive cells (per hpf) in the
ileum of patients with PsA, AS, and CD and healthy controls. K2M, Representative photomicrographs showing IL-22 immunostaining in sam-
ples from a patient with PsA (K), a patient with AS (L), and a healthy control (M). I and N, Representative photomicrographs showing isotype
control staining for IL-17 (I) and IL-22 (N) in samples from patients with PsA. O, Semiquantitative evaluation of IL-222positive cells (per hpf)
in the ileum of patients with PsA, AS, and CD and healthy controls. Values in A2E, J, and O are the mean6 SEM. * 5 P , 0.05 versus con-
trols. Original magnification 3 400 in F, G, and K; 3 100 in H and L; 3 250 in I, M, and N. See Figure 1 for other definitions. Color figure can
be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/journal/doi/10.1002/art.39649/abstract.
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located at the bottom of intestinal crypts highly resem-
bling Paneth cells (Figures 3D and E). IL-9 immuno-
staining was also observed in ileal biopsy specimens
from patients with AS (Figure 3G) and CD (Figure 3H)
and healthy controls (Figure 3I), albeit at a much lesser
degree. Quantification of the immunostaining con-
firmed increased IL-9 staining in PsA patients versus
controls (P, 0.0001), with a similar trend in patients
with CD (P, 0.05), but not in those with AS (Figure 3K
and Supplementary Table 3, http://onlinelibrary.wiley.
com/doi/10.1002/art.39649/abstract). The number of IL-
9–expressing cells correlated with the degree of intesti-
nal inflammation (Supplementary Figure 1A, http://
onlinelibrary.wiley.com/doi/10.1002/art.39649/abstract).
Additionally, we characterized by confocal
microscopy the main intestinal cellular source of IL-9
among infiltrating mononuclear cells and epithelial cells
in PsA patients. CD41 cells were the major source of
IL-9 in the gut of patients with PsA. These cells were
demonstrated to be in large part IL-91PU.11 (Th9)
cells (Figures 4A–D), with double IL-17/IL-9–expressing
(Th17) cells being only rarely present (Figures 4E–G)
and IL-4/IL-9 (Th2)–positive cells virtually absent
(Figures 4H–J). Paneth cells were also demonstrated to
overexpress IL-9 in PsA patients, by colocalization of
IL-9 and a-defensin 5 (Figures 4K–M). Because the
functional role of IL-9 depends on the expression of IL-
9 receptor (IL-9R), we next studied the expression and
tissue distribution of IL-9R. Significantly increased IL-
9R expression was observed, at both the mRNA level
(Figure 5A) and the protein level (Figures 5B2H and J
and Supplementary Table 3, http://onlinelibrary.wiley.
com/doi/10.1002/art.39649/abstract) in the gut of PsA
patients compared to healthy controls, patients with AS,
and patients with CD. Three main patterns of expres-
sion were observed: on the surface of infiltrating inflam-
matory mononuclear cells (Figures 5E and F), among
intraepithelial lymphocytes (Figure 5G), and in the con-
text of epithelial cells located at the bottom of intestinal
crypts, resembling Paneth cells (Figure 5H).
To assess the potential functional consequences
of increased IL-9 expression in the gut of PsA patients,
Figure 3. Interleukin-9 (IL-9) in the gut of patients with PsA. A–C, Relative levels of mRNA for IL-9 (A), PU.1 (B), and interferon regulatory
factor 4 (IRF4) (C), assessed by quantitative reverse transcription2polymerase chain reaction, in ileal samples from patients with PsA and an
ileal histologic score of 0 or 1 (n5 6), PsA and an ileal histologic score of 2 or 3 (n5 19), AS (n5 15), and CD (n5 10) and healthy controls
(n5 20). * 5 P , 0.05 versus controls. D–I, Representative photomicrographs showing IL-9 immunostaining in samples from patients with PsA
(D–F), AS (G), and CD (H) and a healthy control (I). J, Representative photomicrograph showing isotype control staining for IL-9 in a sample
from a patient with PsA. K, Semiquantitative evaluation of IL-92positive cells (per hpf) in the ileum of patients with PsA, AS, and CD and
healthy controls. In A2C and K, each symbol represents an individual subject; horizontal bars show the mean. Original magnification 3 250 in
D2J. NS5 not significant (see Figure 1 for other definitions).
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Figure 4. Production of interleukin-9 (IL-9) by Th9 cells, but not Th17/Th9 cells, in the gut of patients with psoriatic arthritis (PsA). A2D, Th9
cells. Representative images show single staining for IL-9 (A), CD4 (B), and PU.1 (C) and merged triple staining for IL-9, CD4, and PU.1 (D)
in PsA gut samples. E2G, Th17 cells. Representative images show single staining for IL-17 (E) and IL-9 (F) and merged double staining for IL-
17 and IL-9 (G) in PsA gut samples. H2J, Th2 cells. Representative images show single staining for IL-4 (H) and IL-9 (I) and merged double
staining for IL-4 and IL-9 (J) in PsA gut samples. K2M, Paneth cells. Representative images show single staining for IL-9 (K) and a-defensin 5
(L) and merged double staining for IL-9 and a-defensin 5 (M) in PsA gut samples. Original magnification 3 630 in A2D and K2M; 3 250 in
E2J. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/journal/doi/10.1002/art.39649/abstract.
Figure 5. Interleukin-9 receptor (IL-9R) in the gut of patients with PsA. A, Relative levels of mRNA for IL-9R, assessed by quantitative reverse
transcription2polymerase chain reaction, in ileal samples from patients with PsA (n5 25), AS (n5 15), and CD (n5 10) and healthy controls
(n5 20). B2H, Representative photomicrographs showing IL-9R immunostaining in samples from a healthy control (B) and from patients with
AS (C), CD (D), and PsA (E2H). I, Representative photomicrograph showing isotype control staining for IL-9R in a sample from a patient
with PsA. J, Semiquantitative evaluation of IL-9R2positive cells (per hpf) in the ileum of patients with PsA and an ileal histologic score of 0 or
1, PsA and an ileal histologic score of 2 or 3, AS, and CD and healthy controls. * 5 P , 0.05 versus controls. In A and J, each symbol repre-
sents an individual subject; horizontal bars show the mean. Original magnification 3 250 in B2F; 3 400 in G; 3 630 in H; 3 100 in I. NS5 not
significant (see Figure 1 for other definitions). Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/
journal/doi/10.1002/art.39649/abstract.
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we stimulated in vitro–isolated epithelial cells from PsA
gut with IL-9. After IL-9 stimulation, we observed
increased expression of mRNA for a-defensin 5, SOX9,
and IL-23p19 only in isolated epithelial cells from
patients with PsA (Supplementary Figures 1B2D, http://
onlinelibrary.wiley.com/doi/10.1002/art.39649/abstract).
IL-9–secreting peripheral blood lymphocytes
are expanded in PsA patients, express the gut homing
marker a4b7, and correlate with disease activity. We
next evaluated the potential of peripheral blood lym-
phocytes from PsA patients to produce IL-9. As shown
in Supplementary Figures 2A2C (http://onlinelibrary.
wiley.com/doi/10.1002/art.39649/abstract), IL-9–producing
CD41 cells were significantly expanded in the peripheral
blood of PsA patients compared to AS and CD patients
and healthy controls, and expressed PU.1 and a4b7.
Their levels were significantly correlated with disease
activity as assessed by the BASDAI and DAS28 (Supple-
mentary Figure 2D). Although differences in the fre-
quency of Th9 cells among patients with systemic lupus
erythematosus have been reported to be sex-dependent
(23), we observed no difference between male and female
patients with PsA (0.85% in female patients versus
0.81% in male patients; P5 0.8) (data not shown). We
also found that a significantly increased proportion of
peripheral Th9 cells from PsA patients expressed a4b7
integrin (28% in PsA patients versus 4% in controls;
P, 0.05) (Supplementary Figure 2C), suggesting a gut
origin of circulating IL-9–expressing cells in PsA.
IL-9 and IL-9R expression and Th9 cells in
PsA synovial samples. Since synovial tissue is one of
the main targets of inflammation in PsA, we performed
immunohistochemistry analysis to evaluate the expres-
sion of IL-9 and IL-9R in synovial fluid and synovial tis-
sue specimens from PsA patients and controls. IL-9 and
IL-9R were strongly expressed in the samples from PsA
patients (Figures 6A and B) and observed rarely in sam-
ples from patients with OA (Figure 6C). IL-9 was
observed in leukocytic infiltrates and in the synovial lin-
ing layer in patients with PsA, and mainly expressed in
the synovial lining layer and among synovial vessels in
patients with OA. Semiquantitative analysis of immuno-
Figure 6. Th9 and interleukin-9 (IL-9)/IL-9 receptor (IL-9R) in the synovial compartment of patients with psoriatic arthritis (PsA). A2D, Rep-
resentative photomicrographs showing IL-9 immunostaining in synovial tissue from patients with PsA (A and B) and patients with osteoarthritis
(OA) (C and D). E, Semiquantitative evaluation of IL-92positive cells (per high-power field [hpf]) in synovial tissue from patients with PsA and
patients with OA. F, Merged double staining for IL-9 and PU.1 in synovial tissue from a representative PsA patient, demonstrating the presence
of Th9 cells (arrows). G2I, Representative photomicrographs showing IL-9R immunostaining in synovial tissue from patients with PsA (G and
H) and a patient with OA (I). J, Semiquantitative evaluation of IL-9R2positive cells (per hpf) in synovial tissue from patients with PsA and
patients with OA. K and L, Representative photomicrographs showing isotype control staining for IL-9 (K) and IL-9R (L) in synovial tissue
from patients with PsA. M, Representative dot plots showing Th9 cells in synovial fluid from 5 patients with PsA. A large percentage of Th9
cells also expressed a4b7. N, Representative dot plots showing Th9 cells in synovial fluid from 5 patients with OA. O and P, Percentages of Th9
cells (O) and a4b71 Th9 cells (P) in synovial fluid mononuclear cells (SMCs) from patients with PsA and patients with OA. Values in E, J, O,
and P are the mean6 SEM. Original magnification 3 250. Color figure can be viewed in the online issue, which is available at http://onlineli-
brary.wiley.com/journal/doi/10.1002/art.39649/abstract.
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histochemistry results revealed significantly higher
expression of IL-9 in the synovium of patients with PsA
compared to that of patients with OA (Figure 6E and
Supplementary Table 3, http://onlinelibrary.wiley.com/
doi/10.1002/art.39649/abstract). Expression of IL-9 by T
cells was confirmed by confocal microscopy analysis
(Figure 6F), demonstrating that Th9 cells are a source
of IL-9 in PsA synovium. IL-9R was also overexpressed
in leukocytic infiltrates and in the lining layer of PsA
synovium and rarely observed in samples from patients
with OA (Figures 6G–J and Supplementary Table 3).
Flow cytometric analysis demonstrated that Th9 cells
were significantly expanded in the synovial fluid of
patients with PsA compared to that of patients with OA,
and significantly overexpressed a4b7 (Figures 6L–O).
Effects of TNFi and ustekinumab on circulating
Th9 cells. TNFi treatment, and more recently, IL-23
inhibition, have been demonstrated to reduce inflamma-
tion in PsA (24). Nine of the 25 PsA patients enrolled in
this study were treated with golimumab (a TNFi)
(n5 5) or ustekinumab (n5 4), and the frequency of
circulating Th9 cells was reassessed after treatment had
been initiated. At baseline, 2 patients in the TNFi group
and 1 patient in the ustekinumab group did not exhibit
macroscopic alterations on ileocolonoscopy. As shown
in Supplementary Figure 3 (http://onlinelibrary.wiley.
com/doi/10.1002/art.39649/abstract), treatment with
either TNFi or anti2IL-12/IL-23 therapies resulted in a
significant reduction in circulating Th9 cells.
DISCUSSION
In this study, we confirmed the occurrence of
subclinical gut inflammation in PsA patients and pro-
vide the first evidence of a specific histologic and immu-
nologic signature characterized by pronounced Paneth
cell hyperplasia with fully developed Th17 and Th9
responses. The latter was specific to PsA compared to
AS and CD. We also demonstrated that IL-9 overex-
pression and Th9 polarization occur in inflamed synovial
tissue and in the peripheral blood of PsA patients,
leading us to hypothesize that there is a link between
intestinal and synovial inflammation. Finally, clinical
amelioration after treatment with TNFi and ustekinumab
was associated with a significant reduction in circulating
Th9 cells.
The presence of gut inflammation has been pre-
viously demonstrated in the ileal and colonic mucosa of
patients with PsA without bowel symptoms, especially in
those with axial involvement, even when mucosa
appeared macroscopically normal (17,25,26). However,
since in AS significant immune alterations were mainly
found, in earlier studies, at the ileal level (27), we
focused our attention only on the ileal tract. In our
study, both patients with axial involvement and those
with peripheral involvement displayed subclinical ileal
inflammation, with a higher frequency than that
described in previous reports and with similar distribu-
tion between axial and peripheral disease.
Eight PsA patients and 3 AS patients in our
study were taking NSAIDs at the time of ileocolono-
scopy. NSAID-associated ileitis has been described in a
significant proportion of long-term NSAIDs users. His-
tologically, however, it is not easy to distinguish between
NSAID-associated ileitis and CD or AS-associated gut
inflammation. It has been reported that a type of stric-
ture known as “diaphragm disease” is pathognomonic
for NSAID-induced damage (28). We obviously cannot
exclude the possibility that the PsA and AS patients who
were taking NSAIDs had NSAID-related ileitis,
although no stricture were observed in any of the
patients. PsA patients enrolled in our study had high
PASI scores and a relatively short duration of disease
(;40 months in our study, compared to 40 years in the
Belgian study [17]). The proportion of PsA patients with
axial involvement displaying ileal subclinical inflamma-
tion was comparable to that in patients with AS. Unlike
in AS, however, PsA gut inflammation was characterized
by higher numbers of infiltrating inflammatory cells, fre-
quently organized in lymphoid follicles, at levels similar
to those observed in patients with CD.
An increased number of Paneth cells was also
observed in PsA patients. Paneth cells are highly spe-
cialized epithelial cells of the small intestine that reside
at the base of small intestinal crypts involved in the syn-
thesis and secretion of antimicrobial peptides required
for maintenance of crypt sterility and regulation of the
balance of colonizing microbiota and enteric pathogens
(29). Paneth cells originate from the stem cell zone
located in the lower portion of the crypt of Lieberk€uhn,
and their differentiation/hyperplasia seem to be depen-
dent on proinflammatory cytokines such as colony-
stimulating factor 1 (30), IL-9, and IL-13 (31), highlight-
ing the role of inflammation in modulating Paneth cell
differentiation. On the other hand, Paneth cells have
been also demonstrated to participate in the regulation
of several pathways of innate and adaptive immunity,
including that of the IL-23/IL-17 axis (27,32). The pres-
ence of significant intestinal dysbiosis, different from
AS dysbiosis (33), was recently demonstrated in PsA
patients (34). In this context, the increased number of
Paneth cells and the increased levels of antimicrobial
peptides, such as a-defensin 5, demonstrated in the pre-
sent study may suggest the activation of innate defensive
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responses in the PsA gut in response to intestinal
dysbiosis.
Our immunologic characterization of the
inflamed gut of PsA patients demonstrated a distinctive
constellation of immune responses. Similar to previous
findings in AS (27), we did not observe significant up-
regulation of Th1-related cytokines. On the other hand,
different from findings in AS and similar to those in
CD, a fully developed Th17 response, characterized by
strong up-regulation of both IL-17 and IL-22, appears
to be present in the gut of patients with PsA.
Beyond the IL-23/Th17 axis, however, a newly
recognized subset of effector T cells—so-called Th9
cells—has been suggested to play a role in the pathogen-
esis of human inflammatory diseases, and in particular,
psoriasis (35). Although Th9 cells have been shown to
be involved in the pathogenesis of psoriasis, their devel-
opmental origin remains elusive (6,22). In this study we
demonstrated for the first time that IL-9 is strongly
overexpressed by infiltrating inflammatory cells in the
gut of patients with PsA. Among inflammatory cells,
Th9 lymphocytes were the major source of IL-9 in PsA,
highlighting the role of adaptive immunity in the pro-
duction of IL-9. Of note, IL-9 was also produced by
Paneth cells, and these cells also expressed IL-9R.
These data, together with the evidence that stimulation
of epithelial cells with IL-9 up-regulates the expression
of antimicrobial peptides and of cytokines, such as IL-
23, may also suggest the possibility of a functional auto-
crine loop involving IL-9/IL-9R.
Both peripheral arthritis and spine inflammation
occur in patients with PsA. We therefore also evaluated
PsA synovial samples for IL-9 and IL-9R expression,
and demonstrated that both were significantly overex-
pressed. In PsA synovial tissue synovial fibroblasts and
synovial vessels, together with Th9 cells, were found to
be the main source of IL-9. Constitutive production of
IL-9 was also observed in OA synovial samples, in which
endothelial cells and synovial fibroblasts were demon-
strated to produce IL-9.
Th9 cells were also expanded in the peripheral
blood and synovial fluid of PsA patients, and their levels
were correlated with disease activity. The relatively low
percentage of circulating Th9 cells (although significant-
ly increased compared to controls) was similar to that
described in other autoimmune diseases (36), indicating
that these cells probably specifically recirculate at sites
of inflammation. Notably, both circulating and synovial
Th9 cells expressed relatively high levels of the intestinal
homing receptor a4b7, suggesting a predominant
intestinal origin of these cells. Although only a small
number of PsA patients were studied before and after
biologic treatment, in both TNFi- and ustekinumab-
treated patients we observed a significant reduction of
circulating Th9 cells occurring together with clinical
improvement.
In conclusion, specific histologic and immunolog-
ic features seem to characterize the subclinical gut
inflammation in patients with PsA. We also demonstrat-
ed that Th1 is predominant in CD but not in spondy-
loarthritis (AS and PsA), that Th17/22 expression is
increased in all 3 diseases, and most importantly, that
only Th9 cells are specific to PsA. These findings sug-
gest that IL-9 and Th9 cells may play a role in driving
local and systemic inflammation in PsA and might be
considered as a potential future therapeutic target.
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